汉森制药(002412) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 248,851,389.62, representing a 5.72% increase compared to CNY 235,387,600.31 in the same period last year[3] - Net profit attributable to shareholders was CNY 51,824,070.34, up 13.32% from CNY 45,731,537.24 year-on-year[3] - The total operating revenue for Q1 2022 was CNY 248,851,389.62, an increase of 5.8% compared to CNY 235,387,600.31 in Q1 2021[18] - The net profit for Q1 2022 reached CNY 51,824,070.34, representing a growth of 13.5% from CNY 45,731,537.24 in the same period last year[19] - The total comprehensive income for Q1 2022 was CNY 49,185,657.62, compared to CNY 41,997,646.77 in the same period last year, marking an increase of 17.5%[20] - The company's diluted earnings per share increased by 13.31% to CNY 0.1030 from CNY 0.0909 in the previous year[3] - The basic earnings per share for Q1 2022 was CNY 0.1030, an increase from CNY 0.0909 in Q1 2021[20] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 37.91% to CNY 44,016,378.08, down from CNY 70,886,845.47 in the previous year[3] - The cash inflow from operating activities was CNY 249,825,439.23, compared to CNY 242,374,291.24 in the previous year, indicating a growth of 3.0%[21] - The total cash and cash equivalents at the end of Q1 2022 amounted to ¥90,759,367.83, down from ¥133,986,934.55 at the end of Q1 2021[23] - The company reported a total cash outflow from operating activities of ¥205,809,061.15, which is an increase from ¥171,487,445.77 in Q1 2021[23] - The company reported a decrease in cash and cash equivalents by 98.53%, totaling CNY 1,000,000.00 compared to the previous year[8] Research and Development - R&D expenses increased by 35.74% to CNY 8,598,000.00, primarily due to enhanced investment in the consistency evaluation of isoniazid tablets and iodinated contrast agents[6] - Research and development expenses increased to CNY 8,682,027.43, up 35.7% from CNY 6,396,211.92 in Q1 2021[18] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,132,384,519.04, a 1.00% increase from CNY 2,111,282,192.35 at the end of the previous year[3] - The total current assets are RMB 560,644,902.53, up from RMB 535,410,439.63 at the beginning of the year, reflecting a growth of approximately 4.3%[15] - The accounts receivable increased to RMB 245,321,781.67 from RMB 207,401,998.50, indicating a growth of about 18.3%[15] - The total liabilities decreased to CNY 340,906,329.02 from CNY 368,989,659.95 year-over-year, reflecting a reduction of approximately 7.6%[17] - The company's short-term borrowings decreased to RMB 102,901,468.00 from RMB 131,791,855.05, a reduction of approximately 22%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 46,670[10] - The largest shareholder, Hainan Hansen Holdings (Limited Partnership), holds 42.13% of the shares, totaling 212,006,189 shares[10] - The total number of shares held by the top ten unrestricted shareholders includes 212,006,189 shares held by Hainan Hansen Holdings[10] Other Financial Activities - The company completed the registration of business changes and received a new business license on January 8, 2022[12] - The company plans to invest up to RMB 10 million as a limited partner in an industry investment fund with Shenzhen Rongyu Capital Management Co., Ltd.[12] - The company recorded a total of CNY 551,165.57 in non-recurring gains and losses for the reporting period[5] Operating Costs - The total operating costs for Q1 2022 were CNY 199,935,352.92, slightly up from CNY 197,880,670.79 in Q1 2021[18] - The company reported a decrease in sales expenses to CNY 105,570,433.08 from CNY 108,676,129.07 year-over-year, a reduction of 2.0%[18] Audit and Reporting - The company did not conduct an audit for the Q1 2022 report[24] - The report was released by the board of directors on April 28, 2022[25]